|
Re: Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
|
6
|
Resverlogix Corp.
|
Aug 29, 2023 01:39PM
|
|
Re: I believe the big/long wait
|
2
|
Resverlogix Corp.
|
Aug 25, 2023 12:28PM
|
|
Re: Financial Statement Q2, 2023 /MD&A
|
2
|
Resverlogix Corp.
|
Aug 13, 2023 05:07PM
|
|
Re: New SEDAR page
|
|
Zenith Epigenetics
|
Aug 10, 2023 12:55PM
|
|
Re: Additional Reports of Exempt Distribution
|
3
|
Zenith Epigenetics
|
Jul 25, 2023 02:48AM
|
|
Re: For what it’s worth
|
2
|
Zenith Epigenetics
|
Jul 19, 2023 05:13PM
|
|
Re: For what it’s worth
|
2
|
Zenith Epigenetics
|
Jul 19, 2023 05:11PM
|
|
Re: Trodelvy - development history and valuations along the way
|
|
Zenith Epigenetics
|
Jul 04, 2023 02:35PM
|
|
Re: AGM
|
3
|
Resverlogix Corp.
|
Jun 30, 2023 07:38PM
|
|
Re: AGM
|
4
|
Resverlogix Corp.
|
Jun 30, 2023 02:58PM
|
|
Re: TNBC no longer active?
|
4
|
Zenith Epigenetics
|
Jun 28, 2023 04:32PM
|
|
Re: TNBC no longer active?
|
2
|
Zenith Epigenetics
|
Jun 28, 2023 12:10AM
|
|
Re: What's the deal with Zenith?
|
3
|
Zenith Epigenetics
|
Jun 23, 2023 10:24AM
|
|
Re: What's the deal with Zenith?
|
1
|
Zenith Epigenetics
|
Jun 23, 2023 02:15AM
|
|
Re: What's the deal with Zenith?
|
3
|
Zenith Epigenetics
|
Jun 23, 2023 01:54AM
|
|
Re: What's the deal with Zenith?
|
6
|
Zenith Epigenetics
|
Jun 22, 2023 02:26PM
|
|
Re: "Do we actually have a Breakthrough Therapy Designation?"
|
4
|
Resverlogix Corp.
|
Jun 14, 2023 03:37PM
|
|
Re: Resverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patients
|
3
|
Resverlogix Corp.
|
Jun 14, 2023 09:18AM
|
|
Re: Breakthrough Therapy Designation
|
2
|
Resverlogix Corp.
|
Jun 13, 2023 12:26PM
|
|
Breakthrough Therapy Designation
|
1
|
Resverlogix Corp.
|
Jun 13, 2023 12:19PM
|
